참고문헌
- Ang WH, Dyson PJ (2006). Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. Euro J Inorg Chem, 20, 4003-18.
- Beraldo H, Gambino D (2004). The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini-Rev Med Chem, 4, 31-9. https://doi.org/10.2174/1389557043487484
- Bergamo A, Sava G (2007). Ruthenium complexes can target determinants of tumor malignancy. Dalton Trans, 13, 1267-72.
- Bruijnincx PCA, Sadler PJ (2009). Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design. Adv Inorg Chem, 61, 1-62. https://doi.org/10.1016/S0898-8838(09)00201-3
- Brunton LL, Lazo JS, Parker KL (2005). Pharmacological Basis of Therapeutics. MCGRAW- HILL, New York.
- Clairs SA, Paul JD (2001). Ruthenium in medicine: current clinical uses and future prospects. Platinum Met Rev, 45, 62-9.
- Clarke MJ, Zhu F, Frasca DR (1999). Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev, 99, 2511-34. https://doi.org/10.1021/cr9804238
- Clarkson BD, Burchenal JH (1965). Priliminary screening of antineoplastic drugs. Prog Clin Cancer, 1, 625-9.
- Cristiano MP, Cardoso DC, Da Silva Paula MM, Costa-Campos L (2008). Antinociceptive effect of a ruthenium complex in mice. Auton & Autac Pharmacol, 28, 103-8. https://doi.org/10.1111/j.1474-8673.2008.00423.x
- Dyson PJ (2007). Systematic design of a targeted organometallic antitumour drug in pre-clinical development. CHIMIA Int J Chem, 61, 698-703. https://doi.org/10.2533/chimia.2007.698
- Folkman J, Kalluri R (2004). Cancer without disease. Nature, 427, 787. https://doi.org/10.1038/427787a
- Gianferrara T, Bratsos I, Alessio E (2009). A categorization of metal anticancer compounds based on their mode of action. Dalton Trans, 37, 7588-98.
- Gothoskar SV, Ranadive KJ (1971) Anticancer screening of SAN-AB: An extract of marking nut Semicarpus anacardium. Indian J Exp Biol, 9, 372-5.
- Govender P, Renfrew AK, Clavel CM, et al (2011). Antiproliferative activity of chelating N, O- and N, N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds. Dalton Trans, 40, 1158-67. https://doi.org/10.1039/c0dt00761g
- Hadda TB, Mehmetakkurt, Baba MF, et al (2009). Anti-tubercular Activity of Ruthenium(II) Complexes with Polypyridines. J Enzy Inhib Med Chem, 24, 457-63. https://doi.org/10.1080/14756360802188628
- Hartinger CG, Dyson PJ (2009). Bioorganometallic chemistry-from teaching paradigms to medicinal applications. Chem Soc Rev, 38, 391-401. https://doi.org/10.1039/b707077m
- Hartinger CG, Jakupec MA, Zorbas-Seifried S, et al (2008). KP1019, a new redox-active anticancer agent-preclinical development and results of a clinical phase I study in tumor patients. Chem and Biodiver, 5, 2140-55. https://doi.org/10.1002/cbdv.200890195
- Hogland HC (1982). Hematological complications of cancer chemotherapy. Semin Oncol, 9, 95-102.
- Mazumder UK, Gupta M, Maiti S, Mukherjee M (1997). Antitumor activity of Hygrophila spinosa on Ehrlich ascites carcinoma and sarcoma-180 induced mice. Indian J Exp Biol, 35, 473-7.
- Meyer BN, Ferringin NR, Putman JE, et al (1982). Brine shrimp. A convenient general bioassay for active constituents. Planta Medica, 45, 31-4. https://doi.org/10.1055/s-2007-971236
- Newcomb JR, Rivnay B, Bastos CM, et al (2003). In vitro immunomodulatory activity of ruthenium complexes. Inflamm Res, 52, 263-71.
- Noaman E, Zahran AM, Kamal AM, Omran MF (2002). Vitamin E and selenium administration as a modulator of antioxidant defense system: biochemical assessment and modification. Biol Trace Elem Res, 86, 55-64. https://doi.org/10.1385/BTER:86:1:55
- Novakova O, Brabec V (2006). DNA binding mode of Ruthenium complexes and relationship to tumour cell toxicity. Drug Res Updates, 9, 111-22. https://doi.org/10.1016/j.drup.2006.05.002
- Paula MM, Pich CT, Petronilho F, et al (2005). Antioxidant activity of new ruthenium compounds. Redox Rep, 10, 1-6.
- Prasad SB, Giri A (1994). Antitumor effect of cisplatin against murine ascites Dalton's lymphoma. Ind J Exp Biol, 32, 155-62.
- Sava G, Clerici K, Capozzi I et al (1999b). Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumours. Anti-Cancer Drugs, 10, 129-38. https://doi.org/10.1097/00001813-199901000-00016
- Scott MP (2003). A twist in the Hedgehog's tale. Nature, 425, 780-2. https://doi.org/10.1038/425780a
- Sendiero DA, Shoemaker RH, Paul KD (1998). Evaluation of soluble tetrazolium/formazan assay for cell growth % drug sensitivity in cultures using human and other cells lines. Cancer Res, 48, 4827-33.
- Shyam Sunder A, Sreekanth T, Rajeshwar Y, Satyavati D (2012). In Vitro Antioxidant Activity of Some Novel Synthetic Mononuclear Ruthenium(II) Compounds. Lett Drug Design Disc, 9, 421-5. https://doi.org/10.2174/157018012799859927
- Sreekanth T, Karki SS, Jayaveera KN et al (2010). Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes. J Enzyme Inhib Med Chem, 25, 513-9. https://doi.org/10.3109/14756360903357577
- Süss-Fink G (2010). Arene ruthenium complexes as anticancer agents. Dalton Trans, 39, 1673-88. https://doi.org/10.1039/b916860p
- Verweij J, Dejonge MJA (2000). Achievements and future of chemotherapy. Eur J Cancer, 36, 1479-87. https://doi.org/10.1016/S0959-8049(00)00133-7
피인용 문헌
- Antimicrobial and Antimalarial Activity of Novel Synthetic Mononuclear Ruthenium(II) Compounds vol.60, pp.2, 2012, https://doi.org/10.1002/jccs.201200301
- Synthesis, structural elucidation, and in vitro antiproliferative activities of mixed-ligand titanium complexes vol.23, pp.8, 2014, https://doi.org/10.1007/s00044-014-0963-7
- Antitumor effectiveness and mechanism of action of Ru(II)/amino acid/diphosphine complexes in the peritoneal carcinomatosis progression vol.39, pp.10, 2017, https://doi.org/10.1177/1010428317695933
- A biphosphinic ruthenium complex with potent anti-bacterial and anti-cancer activity vol.41, pp.21, 2017, https://doi.org/10.1039/C7NJ02943H